Looking at outcomes with long-acting buprenorphine formulations
Watch the spring educational session that discussed the significance of patient freedom as part of an effective management strategy for opioid dependence, led by Dr Michael Kelleher and joined by Dr Bernadette Hard and (nurse specialist) Mrs Lisa Kieh.
This event explored the sharing of best-practice treatment approaches using long-acting buprenorphine formulations, including patient-reported outcomes and perspectives from a key national pilot. As well as hearing their views, we also heard the perspectives of a patient to learn more about his direct experience with opioid-dependence treatment.
After watching this video, viewers should be able to:
- Explain key differences between the long-acting buprenorphine (BPN) formulations
- Recount patient experiences and outcomes from treatment with long-acting BPN,
as demonstrated from a pilot project in Wales
- Recall the benefits and ways to overcome potential challenges associated with
long-acting BPN (from perspectives of patients and healthcare providers)
1. An introduction to currently available long-acting buprenorphine formulations
Watch Dr Mike Kelleher discuss the available long-acting buprenorphine formulations and the key differences.
2. Patient experiences and outcomes from treatment with long-acting buprenorphine
Watch Dr Bernadette Hard as she provides insights on her direct patient experiences through a pilot scheme in Wales. Also hear directly from a patient about the impact that long-acting buprenorphine treatment has had on his life.
3. Nurse’s perspective on effective management strategy for opioid dependence
Listen to Mrs Lisa Kieh as she talks about her perspective as both as a nurse and commissioner on an effective management strategy for opioid dependence in Wales.
Listen to the Q&A session with all three panellists where they discuss questions from the audience. It was a lively discussion and some of the questions included:
- Can you share your experience on transitioning from methadone?
- Do you think that daily methadone / buprenorphine will become obsolete in the near future?
- Have you experienced many service users with needle phobia?
Dr Michael Kelleher
Consultant Addictions Psychiatrist
South London and Maudsley NHS Foundation Trust, London, England
The IOTOD webinar ‘Can we offer our opioid-dependent patients greater freedom? Looking at outcomes with long-acting buprenorphine formulations’ is supported by grant funding from Camurus. The educational programme is run at arm’s length from the financial supporters and all content is created by the faculty. No funder has had input into the content of the materials or presentations used in the educational programme. PCM Scientific is the medical education company acting as scientific secretariat and webinar organiser.